Quality assessment All included articles were evaluated using the Cochrane Collaborations tool [1149], as outlined in Supplementary Table 3
The weakest part of the argument is that no clinical trial has ever tested this specific combination, the additive effect of levocarnitine on top of tirzepatide substantial metabolic impact may be negligible, and the cost premium is not clearly justified by the expected benefit
Tang WH, Wang Z, Levison BS, et al
This personalized approach reduces trial-and-error treatment and supports safer, more effective weight loss
In addition, since the first evidence of a beneficial effect of GLP-1RAs in BAD treatment was not available until 2019, we notice that the prescriptions of GLP-1RAs up until this year were made for other indications than BAD in contrast to bile acid sequestrants
I can only imagine the results after several months of use